$0.58 Earnings Per Share Expected for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) This Quarter

Equities research analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to announce earnings of $0.58 per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $0.55 to $0.62. Teva Pharmaceutical Industries posted earnings per share of $0.78 in the same quarter last year, which suggests a negative year over year growth rate of 25.6%. The company is scheduled to announce its next quarterly earnings report before the market opens on Wednesday, August 7th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.38 per share for the current year, with EPS estimates ranging from $2.20 to $2.49. For the next year, analysts anticipate that the company will post earnings of $2.54 per share, with EPS estimates ranging from $2.38 to $2.76. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. The business had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.94 EPS.



TEVA has been the subject of a number of analyst reports. Wells Fargo & Co set a $17.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Tuesday, May 28th. Oppenheimer set a $12.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Wednesday, June 12th. Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, June 17th. Wolfe Research initiated coverage on Teva Pharmaceutical Industries in a research note on Friday. They set a “peer perform” rating for the company. Finally, UBS Group cut their target price on Mylan to $23.00 and set a “neutral” rating for the company in a research note on Tuesday, May 28th. Six equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $15.39.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Sol J. Barer bought 111,000 shares of the stock in a transaction on Monday, June 3rd. The shares were bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the acquisition, the director now owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in TEVA. Cutler Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $2,539,000. Bank of New York Mellon Corp grew its stake in Teva Pharmaceutical Industries by 3.5% during the 4th quarter. Bank of New York Mellon Corp now owns 1,975,038 shares of the company’s stock worth $30,454,000 after purchasing an additional 67,168 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in Teva Pharmaceutical Industries by 2.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 76,187 shares of the company’s stock worth $1,175,000 after purchasing an additional 1,497 shares in the last quarter. Great West Life Assurance Co. Can grew its stake in Teva Pharmaceutical Industries by 3.0% during the 4th quarter. Great West Life Assurance Co. Can now owns 428,190 shares of the company’s stock worth $6,273,000 after purchasing an additional 12,515 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in Teva Pharmaceutical Industries by 10.5% during the 4th quarter. California State Teachers Retirement System now owns 732,680 shares of the company’s stock worth $11,298,000 after purchasing an additional 69,457 shares in the last quarter. Hedge funds and other institutional investors own 65.05% of the company’s stock.

Shares of TEVA stock traded up $0.14 during trading hours on Friday, reaching $7.97. 11,931,557 shares of the company’s stock were exchanged, compared to its average volume of 17,633,578. The firm has a market cap of $8.03 billion, a P/E ratio of 2.85, a P/E/G ratio of 0.97 and a beta of 1.62. The business’s 50 day simple moving average is $8.90. Teva Pharmaceutical Industries has a 1 year low of $7.66 and a 1 year high of $25.96. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: What does the Producer Price Index (PPI) tell investors?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.